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Abstract
Background: Staphylococcus aureus is a non-motile, gram positive, non-sporforming, facultative
anaerobic microorganism. It is one of the important bacteria as a potential pathogen specifically for
nosocomial infections. The sulfonamide derivative medicines are preferred to cure infection caused
by S. aureus due to methicillin resistance.
Methods: Antimicrobial activity of four sulfonamide derivatives have been investigated against 50
clinical isolates of S. aureus and tested by using MIC and disc diffusion methods. 50 clinical isolate
which collected from specimens of patients who are given medical treatment in Ondokuz Mayis
University Medical School Hospital. A control strain of S. aureus ATCC 29213 was also tested.
Results: The strongest inhibition was observed in the cases of I [N-(2-hydroxy-4-nitro-phenyl)-4-
methyl-benzensulfonamid], and II  [N-(2-hydroxy-5-nitro-phenyl)-4-methyl-benzensulfonamid]
against S. aureus. Compound I [N-(2-hydroxy-4-nitro-phenyl)-4-methyl-benzensulfonamid] showed
higher effect on 21 S. aureus MRSAisolates than oxacillin antibiotic. Introducing an electron
withdrawing on the ring increased the antimicrobial activity remarkably.
Conclusion:  This study may help to suggest an alternative possible leading compound for
development of new antimicrobial agents against MRSA and MSSA resistant S. aureus. It was also
shown here that that clinical isolates of 50 S. aureus have various resistance patterns against to four
sulfonamide derivatives. It may also be emphasized here that in vitro antimicrobial susceptibility
testing results for S. aureus need standardization with further studies and it should also have a
correlation with in vivo therapeutic response experiments.
Background
Staphylococcus aureus is one of the most significant human
pathogens responsible for nosocomial and community
acquired infections. It can cause a range of infectious dis-
ease from mild conditions, such as soft tissue infections,
to severe life-threatening debiliation, such as endocarditis
[1]. Despite the recent staphylococci infections, they are
persisting as an important hospital and community path-
ogen [2]. Methicillin resistance has become a major con-
cern to the medical community due to the fact that they
have an extraordinary ability to adapt rapidly to antibiotic
stress [3]. Among hospital isolates the frequency of methi-
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cillin resistant S. aureus (MRSA) is very high [4]. There is
need to have new chemicals for treatment of staphyloco-
cci infections.
The sulfonamides have, for many years, being widely
studied for their chemotherapeutic activity. Their impor-
tant role as antibacterial, antimalarial and antileprotic
agents is well recognized [5,6]. Recently, certain sulfona-
mides have been reported as showing interesting the anti-
bacterial properties of sulfonamides have been extensively
studied by Quantitive Structure-activity Relation-
ship&Molecular Modeling (QSAR) method. [7]. Antimi-
crobial therapy for infections with S. aureus often includes
sulfonamides which are use to cure nosocomial infections
[1]. Sulfonamides are still an alternative option in order to
cure methicillin resistant S. aureus (MRSA) staphylococci
infections. Although the sulfonamide therapy has been
reduced, owing to development of more effective antimi-
crobial agents and to the gradual increase in the resistance
of bacterial species, clinical treatment with sulfonamides
has undergone a revival by the combination sulfomethox-
azole and trimethoprim.
Considering this background, the objective of this study
some sulfonamides derivatives were tested in terms of
antimicrobial activity with the purpose of revealing possi-
ble leading compounds for development of new antimi-
crobial agents against methicillin resistant S. aureus
(MRSA) and methicillin sensitive S. aureus MSSA.
Methods
Preparation of the sulfonamides
General procedure for preparation of the sulfonamides is
as follows [8]. For a typical run; 0.06 mol substituted ani-
line was dissolved in 30 ml benzene. 0.06 mol p-tolue-
nesulfonylchloride in 20 ml benzene was added into the
solution. 0.06 mol dry pyridine was added into 20 ml
benzene slowly and it was refluxed for 4 h, so the solvent
was removed and a solid was obtained. The solid was dis-
solved in 10% (w/II) NaOH solution and extracted with
CHCl3. Aqueous solution was acidified with HCl to
obtain raw sulfonamide. Recrystallization of ethanol-
water mixture from raw sulfonamide resulted in corre-
sponding sulfonamide in pure form [9]. Some physical
and spectral data of the synthesized sulfonamides were
summarized below:
N-  (2-Hydroxy-4-nitro-phenyl)-4-methyl-benzenesulfona-
mide (I) m.p. 181–182°C. 1H NMR (acetone-d6), δ(ppm)
2.23 (s,3H), 3.37 (s,1H), 7.34 (d,2H), 7.63 (d,2H), 7.71
(dd,1H), 7.82 (d,2H), 8.65 (s,1H), 10.99 (s,1H); IR (KBr)
3608 (OH), 3270 (NH), 3079 (Ar-H), 2920, 1596, 1525
(NO2 asym.), 1446, 1402, (SO2 asym.), 1336 (NO2 sym.),
1270, 1162, 1128 (SO2 sym.) cm-1 [3].
N-(2-Hydroxy-5-nitro-phenyl)-4-methyl-benzenesulfona-
mide  (II)  m.p. 208–209°C. 1H NMR (acetone-d6),  δ
(ppm) 2.32 (s,3H), 3.60 (broad,1H,-NH), 6.97 (d,1H),
7.31 (d,2H), 7.75 (d,2H), 7.87 (dd,1H), 8.33 (d,1H),
8.55 (broad,1H,-OH); IR (KBr) 3407 (OH), 3280 (NH),
3085 (Ar-H), 2930, 1596, 1523 (NO2 asym.), 1454, (SO2
asym.), 1342 (NO2 sym.), 1164 (SO2 sym.) cm-1 [4].
N-(5-Chloro-2-hydroxy-phenyl)-4-methyl-benzenesulfona-
mide  (III)  m.p. 189–190°C. 1H NMR (acetone-d6),  δ
(ppm) 2.35 (s,3H), 3.55 (broad,1H,-NH), 6.79 (d,1H),
6.92 (dd,1H), 7.31 (d,2H), 7.36 (d,1H), 7.71 (d,2H),
8.62 (broad,1H,-OH); IR (KBr) 3450 (OH), 3259 (NH),
3080, 2930, 1602, 1504, 1440, 1384, 1319 (SO2 asym.),
1216, 1170 (SO2 sym.) cm-1 [3].
N-(2-Hydroxy-5-methyl-phenyl)-4-methyl-benzenesulfona-
mide  (IV))  m.p. 142–143°C. 1H NMR (acetone-d6),  δ
(ppm) 2.14 (s,3H), 2.33 (s,3H), 3.47 (broad,1H,-NH),
6.67 (d,1H), 6.74 (dd,1H), 7.13 (s,1H), 7.27 (d,2H), 7.67
(d,2H), 8.46 (broad,1H,-OH); IR (KBr) 3370 (OH), 3247
(NH), 3039, 2917, 1596, 1517, 1446, 1390, 1321 (SO2
asym.), 1290, 1245, 1187, 1162, 1112 (SO2 sym.) cm-1
[3].
Bacterial strains and inoculums preparation
As a preliminary screening for antimicrobial activity of 4
sulfonamides were tested against 30 meticillin resistant
(MRSA) and 20 susceptible (MSSA) clinical isolates of Sta-
phylococcus aureus provided by Ondokuz Mayis University,
Medical School Department of Microbiology and Infec-
tious disease. MRSA isolates were determined by oxacillin
test. The commonly used method in routine laboratory
practice for the detection of methicillin resistance is oxa-
cillin disc diffusion. All the clinical isolates were isolated
from patients in the hospital. Each Staphylococcus aureus
isolates were cultured in nutrient broth before the antimi-
crobial activity test performed. Each isolate was checked
for its purity and several colonies were emulsified into 50
ml nutrient broth (LabM). The inoculated flasks were
incubated at 37C for 18 h on a rotary shaker at 150 rpm
(GFL 3032). Reference strain of Staphylococcus aureus
ATCC 29213 was used as control strain reference strain in
order to monitor the antimicrobial disc susceptibility test
[10].
Antimicrobial activity Screening
Antimicrobial studies were performed according to agar
disc diffusion method [11]. To obtain more significant
information as to the antibacterial potency of sulfona-
mides derivatives compound I, II, III, and IV against Sta-
phylococcus aureus, subcultures were carried out and
minimal bactericidal concentration were determined. The
following test conditions were applied; all the com-
pounds were dissolved in dimethylsulfoxid (DMSO,Annals of Clinical Microbiology and Antimicrobials 2008, 7:17 http://www.ann-clinmicrob.com/content/7/1/17
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Merck). Sensitest agar (Oxoid) plates were prepared and
dried at 35–36°C for about 30 min in an incubator. Test
strains were spreaded on solid sensitest agar surface by
using sterile swap. Spreaded inoculums were 3.5 × 105 col-
ony forming unit/ml-1 (0.5 McFarland standards, Biomer-
iux Colorimeter). At the same time, absorbent paper discs
were placed on agar surface (5 mm for compounds and 6
mm for antibiotics)and impregnated with known concen-
trations which determined previously by MIC tests (500
μg for each disc). Oxacillin 1 μg (Oxoid) and Trimeto-
prim-Sulfametaksazol 23.75 μg were also used for all test
microorganisms as positive control. Blank test showed
that DMSO in the preparations of the test solutions does
not affect the test organisms. They were inverted and
allowed to incubate at 37°C. The inhibition zone around
the disc was calculated edge to edge zone of confluent
growth which is usually corresponds to the sharpest edge
of the zone and to be measured diameter in millimeter.
All tests were repeated tree times and average data taken as
final result.
Results and discussion
Methicillin-resistant staphylococci are resistant to all
other penicillin, carbapenems, cephems and beta-lactam,
beta-lactam inhibitor combinations [11]. Consequently
these antibiotics should not be used for treating of methi-
cillin-resistant staphylococci infections. Moreover,
recently several studies have shown that the methicillin-
resistant staphylococci have started to gain resistance to
some other widely used antibiotics (quinolone, macrolide
group antibiotics, amino glycosides, tetracycline, trimeto-
prim sulphamethoxazole (SXT), clindamicin, chloram-
phenicol as well [12-15]. The resistance increase
trimetoprim-sulphametoxazole, which is an alternative
medicine in the treatment of methicillin-resistant staphy-
lococci infections, is recently received attention. Previ-
ously, trimetoprim-sulphametoxazole resistance has been
shown to be 10–53% in Turkey while it was reportedly
higher (47–79%) in European countries [16]. Trimeto-
prim-sulphamethoxazole is used for the treatment of sta-
phylococci infections. SXT has still maintain its' an
alternative antibiotic potential for the treatment of MRSA
and MSSA infections [1]. In addition, sulphametizol, sul-
phamethaxozole or sulphisoxazole have been using for
the treatment of E. coli urinary infection as a single antibi-
otics [1].
In this study, the in vitro antibacterial activity properties
of the compounds tested on clinical isolates of 30 MRSA
and 20 MSSA S. aureus by using new sulfonamide deriva-





mide(IV). Some of the sulfonamides were found to be
effective on S. aureus among the others. The strongest
inhibition was detected by the effect of (N-(2-Hydroxy-4-
nitro-phenyl)-4-metil-benzensulfonamide) (I). The simi-
lar results were obtained in previous studies against Nocar-
dia  species by the treatment of the same sulfonamide
compound (Isik and Özdemir-Koçak, article in press in
Microb. Res.)
First of all, we tried to find out (Minimal Inhibitory Con-
centrations) MIC values of sulfonamides derivatives
against S. aureus isolates. The rate of MIC values showed
alterations from 32 to 512 μg for 50 isolates. All data are
given in Table 1 indicated that MIC values was not the
same for all isolates i.e. showed variations in terms of
resistance. It was given in the literature that treatment of
some infections 300 μg sulfafurazol and sulfisoxazole ST
are applied to patients [10]. After determining the mini-
mum and maximum MIC values, suitable concentration
was selected for all isolates in order to proper comparison.
It means, MIC values given in table 1 showed that sulfon-
amide derivatives I and II given here area potential anti-
bacterial substances. It was also reported that I, and II
numbered substances showed strong antibacterial activity
against  Staphylococcus aureus ATTCC 43300 and some
other gram positive bacteria [17]. Here tested compounds
I, II, and III showed antibacterial activity against reference
strain  S. aureus ATTCC 29213 and their concentration
were 32, 64 and 128 μg respectively. Compound I was
found as a strongest antibacterial agent against S. aureus
Table 1: MIC values of sulfonamides derivatives I, II, and III against total 50 S. aureus clinical isolates (data given as percentage). 
Compound I Compound II Compound III
MICs (μg) Number of susceptible Isolates (%) Number of susceptible Isolates (%) Number of susceptible Isolates (%)
32 3 (6) 0 (0) 0 (0)
64 14(28) 6 (12) 0 (0)
128 19 (38) 39 (78) 18 (36)
256 12 (24) 5 (10) 22 (44)
512 2 (4) 0 (0) 10 (20)
Compund IV showed very low activity therefore it was not taken in consideration.Annals of Clinical Microbiology and Antimicrobials 2008, 7:17 http://www.ann-clinmicrob.com/content/7/1/17
Page 4 of 6
(page number not for citation purposes)
according to MIC values. The MIC values showed some
alterations according to S. aureus strains given in Table 1.
Secondly, antimicrobial activity of compounds was tested
according to disc diffusion method on the base of MIC
values. 500 μg concentrations were chosen as a suitable
concentration which showed an effect to all S. aureus iso-
lates. All data related to inhibition zones against S. aureus
were given in Table 2. As regard to results the strongest
inhibition was observed in case of compound I. In gen-
eral, the ratio of inhibition caused by Compound I, II and
III were 84%, 50% and 36% respectively (Table 3).
Early and recent researchers have suggested that sulfona-
mides are useful for the treatment of some staphylococci
infections, especially against urinary infections [1]. In this
study, some sulfonamides derivatives were tested in terms
of antimicrobial activity with the purpose of revealing
possible leading compounds for the development of new
antimicrobial agents. Outcome of the study showed that
sulfonamide derivatives I and II have proved to be effec-
tive enough, which is comparable with previous studies
[17]. It was reported that, sulfonamide I and II showed
the highest inhibitory effect on gram positive bacteria i.e.
S. aureus, N. asteroides, N. farcinia and B. subtilis. On the
contrary, they did not lead to significant inhibitory effect
on gram negative bacteria and also yeast and mould
namely E. coli, P. aeruginosa, E. cloaceae, a yeast C. albicans
and a mould A. niger [17].
Many attempts have been made to relate the antibacterial
behavior of sulfonamides with molecular structure [6]. It
was shown here that antimicrobial activities of the sulfon-
amides were increased when introducing electron with-
drawing groups into the benzene ring of the compounds
(Table 2). The compound I has NO2 group in para posi-
tion according to the sulfonamide group which showed
the strongest effect on the S. aureus. Ionization is impor-
tant factor on antimicrobial effect of sulfonamides due to
increasing solubility. The behaviors of o-substituted acids
are often anomalous [18]. Their strength is sometimes
found to be much greater than expected due to direct
interaction between the adjacent groups. For example, o-
hydroxybenzoic acid is 10 times stronger than p-hydroxy-
benzoic acid. In the case of the sulfonamides, possibly the
OH group in the ortho position stabilize the developing
negative charge on the nitrogen through intramolecular
hydrogen bonding, and in this way the ionization
increases. As can be seen in table 2 the compound I is
more effective against the bacteria possibly due to increas-
ing ionization of N-H group which is enhanced by p-NO2
group. OH group in ortho position is also supports ioni-
zation by involving intramolecular hydrogen bonding.
Introducing NO2 group to meta position (compound II)
reduces antimicrobial activity in general this is because of
lesser effect of this position on N-H group. Chlorine sub-
stituted sulfonamide III has a weaker antimicrobial activ-
ity than NO2  substituted ones due to less electron
withdrawing ability of the chlorine. This is also supported
by the results obtained by compound IV which has CH3
group in meta position. Methyl group donates electron to
the benzene ring therefore reduces the ionization dramat-
ically of the compound. The correlation of antimicrobial
activity with chemical facts of the current study are also in
line with biological activity results [19].
Antimicrobial activities of the sulfonamides depend on
substituent and their position in the benzene ring. While
electron releasing group decreases, electron withdrawing
groups enhanced the activity of the sulfonamides against
S. aureus isolates. Although sulfonamide-based therapy is
generally effective, optimal treatment could be guided by
antimicrobial susceptibility testing of isolates. Moreover,
experimental data show that compound I may also be
considered as a broad spectral effective sulfonamide at
128 μg (78% in total isolates) against MRSA and MSSA S.
aureus isolates. Although 30 out of 50 S. aureus isolates
showed resistance to oxacillin antibiotic, 21 of them were
susceptible mainly to compound I and II.
Conclusion
Sulfonamides are still an alternative option in order to
cure MRSA staphylococci infections. However, increasing
resistance against sulfonamides is a serious problem
recently that has been taken attention. Therefore, there is
need to have new chemicals for treatment of staphyloco-
cci and other bacterial infections. Outcome of the study
has two noteworthy features. This study may help to sug-
gest an alternative possible leading compound for devel-
opment of new antimicrobial agents against MRSA and
MSSA resistant S. aureus. It was also shown here that that
clinical isolates of 50 S. aureus have various resistance pat-
terns against to four sulfonamide derivatives. It may also
be emphasized here that in vitro antimicrobial suscepti-
bility testing results for S. aureus species need standardiza-
tion with further studies and it should also have a
correlation with in vivo therapeutic response experiments
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Table 2: Measured inhibition zone in diameter (mm) of sulfonamide derivatives (I-IV) (500 μg) against clinical isolates of Staphylococcus 
aureus.
S. aureus Isolation Number Compound II Compound II Compound III Compound IV OX (mm) SXT (mm)
SAY01(MRSA) 20 14 5 0 0 24
SAY02(MRSA) 22 15 11 0 0 25,5
SAY03(MRSA) 26 17 10 0 0 28,5
SAY04(MSSA) 19 17 13 0 13,5 28,5
SAY05(MSSA) 23 18 16 0 13,5 28
SAY06(MRSA) 23 18 10 8 0 26
SAY07(MRSA) 25 18 19 8 0 25
SAY08(MRSA) 26 19 13 0 0 26
SAY09(MRSA) 19 16 10 0 0 24
SAY10(MRSA) 25 17 11 7 0 23
SAY11(MRSA) 25 13 11 9 0 27
SAY12(MRSA) 29 19 11 9 0 25,5
SAY13(MRSA) 13 14 10 9 0 25
SAY14(MRSA) 23 17 15 8 0 25
SAY15(MRSA) 21 14 14 0 0 26,5
SAY16(MRSA) 25 18 13 0 0 27
SAY17(MSSA) 21 18 15 0 21 28,5
SAY18(MRSA) 25 16 13 0 0 23,5
SAY19(MSSA) 21 16 16 0 18,5 27
SAY20(MRSA) 26 15 15 0 0 25
SAY21(MSSA) 19 14 13 0 17,5 30,5
SAY22(MRSA) 23 14 15 0 0 27
SAY23(MSSA) 20 16 13 9 20,5 28
SAY24(MSSA) 14 15 14 0 17,5 30
SAY25(MSSA) 12 20 10 0 26 31
S. aureus ATCC 29213 26 17 12 10 20 31
SAY26(MSSA) 28 25 15 0 23 32,5
SAY27(MSSA) 19 11 14 9 18 28
SAY28(MRSA) 28 19 11 8 0 26,5
SAY29(MRSA) 18 17 10 10 0 26,5
SAY30(MRSA) 20 13 12 0 0 23,5
SAY31(MRSA) 26 20 14 0 0 26
SAY32(MSSA) 21 15 14 10 19 26,5
SAY33(MSSA) 18 12 14 11 19 28
SAY34(MRSA) 16 18 10 10 0 23,5
SAY35(MSSA) 20 22 14 0 17 30
SAY36(MSSA) 25 16 16 9 20,5 30
SAY37(MRSA) 13 15 11 8 0 22
SAY38(MRSA) 27 17 10 0 0 25
SAY39(MRSA) 15 14 10 0 0 25,5
SAY40(MSSA) 18 16 11 0 18 25,5
SAY41(MSSA) 27 19 10 11 13 25,5
SAY42(MSSA) 18 17 14 8 22,5 30
SAY43(MRSA) 21 11 14 9 0 28
SAY44(MRSA) 21 16 11 0 0 27,5
SAY45(MSSA) 17 18 11 0 18,5 30
SAY46(MSSA) 14 11 12 0 14,5 21,5
SAY47(MRSA) 22 13 12 8 0 26,5
SAY48(MRSA) 14 18 11 0 0 25,5
SAY49(MRSA) 18 17 12 0 0 27
SAY50(MSSA) 21 22 12 0 20 31
S. aureus ATCC 29213 26 17 12 10 20 31
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